Nightingale Health

We’re more than a lab. We’re your partner in science. 🧑⚕️   Rooted in medical research and backed by deep domain expertise, we guide you to the most relevant panels and help you make sense of your data, so you can move forward with confidence.   Our Multiomics Hub is designed for research needs - follow us to learn more! #Multiomics #Metabolomics #Proteomics

Terveystalo and Nightingale Health deepen strategic partnership – preventive healthcare available to all Terveystalo customers in Finland   Nightingale Health and Terveystalo have signed a new agreement that significantly deepens the strategic partnership between the two companies, advancing innovative healthcare. To date, more than 200,000 Finns have received Nightingale test results as part of Terveystalo’s occupational health checks. Since 2024, the analysis has been included in occupational health services, and the newly signed agreement now makes it available to all customers.   “Preventive health is at the core of Terveystalo’s operations. Collaboration with an innovative technology company has provided our customers with unique insight into their own health and health promotion. Terveystalo and Nightingale share a vision of transferring the focus even more strongly toward disease prevention. This new agreement strengthens our preventive services and enables broader adoption of scalable and cost-effective methods in clinical practice,” says Ilse Rauhaniemi, MD, Medical Director of Preventive Health Care and Obesity Care, Terveystalo.    Read more from the link in the comments. 

Don’t miss our multiomics webinar today! 📣 Join us at 3 p.m. CET for the webinar "Multiomics from a single blood sample: combining Nightingale metabolomics with NULISA proteomics to brain health research and beyond" hosted by Peter Würtz (Nightingale Health) and Michael Evans (Alamar Biosciences, Inc.).   👉 Learn more and register via the link in the comments. See you soon!

The Guardian features Nightingale Health’s technology for detecting disease risk 10 years before symptoms appear from a simple blood test. Our technology, used in the UK Biobank – the world’s largest health study – enables a fundamental shift in healthcare towards prevention.   By analysing metabolic profiles, our technology can provide a more comprehensive picture of health and disease than many other tests, capturing both effects of genetic predispositions and environmental influences, as highlighted in The Guardian article.   Nightingale Health’s mission to shift the emphasis of healthcare from treatment to prevention began more than a decade ago, and we’ve been honoured to collaborate with UK Biobank over the years. Today, our technology is the world’s first 'omics platform in nationwide primary healthcare use, and we continue working to make prevention the new standard of care globally.   Our Chief Scientific Officer, Jeffrey Barrett, will share more insights on this topic at the UK Biobank Scientific Conference in December, where he’ll present the science behind these findings.   Read the full article in The Guardian by Ian Sample: https://lnkd.in/eHyXBE8S

Nightingale Health announces that the full set of metabolic biomarker data it has generated for UK Biobank is now being made available to researchers. This release marks the first time that the complete metabolic profiles of all 500,000 UK Biobank participants are accessible for scientific use worldwide.   UK Biobank is the world’s most comprehensive source of health data, widely used by researchers to advance understanding of human health and disease. With over 2.8 million blood samples analysed to date and more than 900 scientific publications leveraging its technology, Nightingale Health has established itself as the global gold standard in population studies and large biobanks.   "These metabolomic data represent the next link in the chain of UK Biobank’s unparalleled data offering to scientists seeking to improve public health. When combined with the genetic, proteomic and imaging information, these data open up a new dimension of discovery, allowing scientists to study the combined effects of genes, proteins and environmental factors on our health, providing us with new insights into the real-time state of a patient," said Professor Sir Rory Collins, Principal Investigator and Chief Executive of UK Biobank.    Learn more from our press release, link in the comments. 

Are you coming to Diabetes Canada Professional Conference 2025 in Toronto? Come meet our team at booth 906 and hear more about Nightingale Health’s affordable metabolomics and scalable remote blood collection. You can now order both metabolomic and proteomic analysis from the same samples.

Welcome to our webinar “Multiomics from a single blood sample: combining Nightingale metabolomics with NULISA proteomics to brain health research and beyond” on 25 November at 3 p.m. CET!
The webinar will be run jointly by Peter Würtz from Nightingale Health and Michael Evans from Alamar Biosciences, Inc. Learn more and sign up from the link in the comments.

New multiomics horizons: Nightingale Health now offers Alamar Biosciences, Inc. NULISA CNS and Inflammation proteomics   Our metabolomics platform has profiled some of the world’s largest biobanks and clinical studies, delivering detailed metabolic fingerprints. Adding ultra-sensitive proteomics introduces a new layer of biological insight – connecting metabolic function with protein-level signals that influence brain, immune, and systemic health.   👉 Learn more from our new research blog post: https://lnkd.in/dv2kPJCn

🧬 We at Nightingale Health have partnered with Alamar Biosciences, Inc. to bring brain health proteomics into our multiomics platform.   With just one blood sample, we now offer researchers access to both cardiometabolic and neurodegenerative disease insights, powered by our metabolomics and Alamar’s NULISA™ proteomics.   🔍 Available now for research and clinical studies worldwide – to learn more, sign up for our upcoming webinar. Link in the comments.    #Multiomics #Metabolomics #Proteomics 

🌍 Next week, Helsinki becomes the heart of European public health!   We’re excited to attend the 18th EPH Conference, taking place 11–14 November at Finlandia Hall. This year’s theme, “Investing for Sustainable Health and Well-Being,” highlights the vital role of public health in building resilient, equitable societies.   Meet us at the event at our booth 18!